{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:40:02Z","timestamp":1791830402547,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":272,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81360351"],"award-info":[{"award-number":["81360351"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81660512"],"award-info":[{"award-number":["81660512"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1136\/esmoopen-2019-000621","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T04:15:13Z","timestamp":1582172113000},"page":"e000621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1016","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct03571126","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5021-3739","authenticated-orcid":false,"given":"Jian-Guo","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Han","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo S.","family":"Gaipl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2019-000621_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/esmoopen-2019-000621_bb0015","first-page":"497","article-title":"Chemotherapy-Induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings","volume":"15","author":"Cohen","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2019-000621_bb0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","article-title":"Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents","volume":"73","author":"Navari","year":"2013","journal-title":"Drugs"},{"key":"10.1136\/esmoopen-2019-000621_bb0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1634\/theoncologist.2014-0229","article-title":"Aprepitant and fosaprepitant: a 10-year review of efficacy and safety","volume":"20","author":"Aapro","year":"2015","journal-title":"Oncologist"},{"key":"10.1136\/esmoopen-2019-000621_bb0030","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000621_bb0035","first-page":"675","article-title":"Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial","volume":"24","author":"Abe","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2019-000621_bb0040","first-page":"607","article-title":"A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation","volume":"25","author":"Nakagaki","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2019-000621_bb0045","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1634\/theoncologist.2018-0140","article-title":"Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis","volume":"24","author":"Yokoe","year":"2019","journal-title":"Oncologist"},{"key":"10.1136\/esmoopen-2019-000621_bb0050","first-page":"Cd012555","article-title":"Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults","volume":"9","author":"Sutherland","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/esmoopen-2019-000621_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.critrevonc.2017.02.017","article-title":"Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis","volume":"112","author":"Yoodee","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/esmoopen-2019-000621_bb0060","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000621_bb0065","first-page":"1315","article-title":"The efficacy and safety of olanzapine in the treatment of highly and moderately emetogenic chemotherapy induced nausea and vomiting","volume":"30","author":"He","year":"2018","journal-title":"Med J West China"},{"key":"10.1136\/esmoopen-2019-000621_bb0070","first-page":"124","article-title":"Observation on the curative effect of olanzapine combined with conventional antiemetic drugs on chemotherapy-associated vomiting","volume":"10","author":"Guo","year":"2018","journal-title":"China Continuing Medical Education"},{"key":"10.1136\/esmoopen-2019-000621_bb0075","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","article-title":"A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000621_bb0080","first-page":"2381","article-title":"Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis","volume":"24","author":"Chiu","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2019-000621_bb0085","doi-asserted-by":"crossref","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"key":"10.1136\/esmoopen-2019-000621_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1136\/esmoopen-2019-000621_bb0095","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13643-017-0630-4","article-title":"Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes","volume":"6","author":"Chen","year":"2017","journal-title":"Syst Rev"},{"key":"10.1136\/esmoopen-2019-000621_bb0100","article-title":"The adverse events of oxycodone in cancer-related pain: a systematic review and meta-analysis of randomized controlled trials","volume":"95","author":"Ma","year":"2016","journal-title":"Medicine"},{"key":"10.1136\/esmoopen-2019-000621_bb0105","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"10.1136\/esmoopen-2019-000621_bb0110","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jpainsymman.2017.07.025","article-title":"Opioid-Induced constipation relief from fixed-ratio combination prolonged-release oxycodone\/naloxone compared with oxycodone and morphine for chronic nonmalignant pain: a systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Huang","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"10.1136\/esmoopen-2019-000621_bb0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jclinepi.2019.11.011","article-title":"P value-driven methods were underpowered to detect publication bias: analysis of Cochrane review meta-analyses","volume":"118","author":"Furuya-Kanamori","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1136\/esmoopen-2019-000621_bb0120","first-page":"145","article-title":"Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study","volume":"25","author":"Mukhopadhyay","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2019-000621_bb0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1756-9966-28-131","article-title":"Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting","volume":"28","author":"Tan","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1136\/esmoopen-2019-000621_bb0130","first-page":"2","article-title":"The effect of tropisetron combina dexamethasone plus olanzapine in preventing nausea and vomiting in lung cancer patients received chemotherapy","volume":"9","author":"Chen","year":"2015","journal-title":"Chin J Mod Drug Appli"},{"key":"10.1136\/esmoopen-2019-000621_bb0135","first-page":"2673","article-title":"The clinical observation of small dose of olanzapine to prevent and control nausea and vomiting after chemotherapy","volume":"23","author":"LI","year":"2015","journal-title":"Modern Oncology"},{"key":"10.1136\/esmoopen-2019-000621_bb0140","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.11569\/wcjd.v24.i7.1117","article-title":"Olanzapine combined with normal antiemetic drugs in patients on solid tumor chemotherapy: antiemetic effect and impact on quality of life","volume":"24","author":"Meng","year":"2016","journal-title":"World Chinese Journal of Digestology"},{"key":"10.1136\/esmoopen-2019-000621_bb0145","first-page":"1","article-title":"To explore the effects of olanzapine combined with granisetron and dexamethasone in the prevention of chemotherapy-induced emesis nausea and the sleep disorder in cancer patients","volume":"14","author":"Wang","year":"2016","journal-title":"Guide of China Medicine"},{"key":"10.1136\/esmoopen-2019-000621_bb0150","first-page":"251","article-title":"Low dose olanzapine alleviates delayed nausea and vomiting induced by highly emetogenic hemotherapy in female lung cancer patient","volume":"23","author":"Liu","year":"2017","journal-title":"Journal of Chinese Ontology"},{"key":"10.1136\/esmoopen-2019-000621_bb0155","first-page":"118","article-title":"Antiemetic efficacy of olanzapine in breast cancer neoadjuvant chemotherapy","volume":"36","author":"Tian","year":"2017","journal-title":"China & Foreign Medical Treatment"},{"key":"10.1136\/esmoopen-2019-000621_bb0160","first-page":"156","article-title":"The effect of olanzapine for prevention of nausea and vomiting in medium and high emetogenic chemotherapy","volume":"5","author":"Zhao","year":"2018","journal-title":"Journal of Clinical Medical"},{"key":"10.1136\/esmoopen-2019-000621_bb0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12032-017-1074-3","article-title":"Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy","volume":"35","author":"Mehra","year":"2018","journal-title":"Med Oncol"},{"key":"10.1136\/esmoopen-2019-000621_bb0170","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpainsymman.2004.04.008","article-title":"Olanzapine-Induced delirium in a terminally ill cancer patient","volume":"28","author":"Morita","year":"2004","journal-title":"J Pain Symptom Manage"},{"key":"10.1136\/esmoopen-2019-000621_bb0175","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0959-8049(97)00160-3","article-title":"A double-blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy","volume":"33","author":"Kirchner","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2019-000621_bb0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1136\/esmoopen-2019-000621_bb0185","first-page":"1001","article-title":"Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review","volume":"24","author":"Chow","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2019-000621_bb0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","article-title":"Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial","volume":"10","author":"Saito","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000621_bb0195","article-title":"Olanzapine combined with 5-HT3 RA plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Zhou","year":"2019","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2019-000621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:24:03Z","timestamp":1761855843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920300181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["S2059702920300181"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000621","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000621","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000621"}}